Paradigm Biocapital Advisors LP
About Paradigm Biocapital Advisors LP’s 13F portfolio
Paradigm Biocapital Advisors LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Paradigm Biocapital Advisors LP reported $5.3B across 28 US-listed positions (). Its largest position is REVOLUTION MEDICINES INC (RVMD) at 22% of the reported book, and its ten biggest holdings make up 75% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: RVMD REVOLUTION MEDICINES INC | $159.43 −0.24% | 22% | 6.4M | $1.2B |
| 2 | NASDAQ: NUVL NUVALENT INC | $123.96 0.00% | 14% | 5.9M | $731.7M |
| 3 | NASDAQ: EWTX EDGEWISE THERAPEUTICS INC | $41.17 −0.48% | 7.8% | 10.2M | $415.1M |
| 4 | NASDAQ: GMAB GENMAB A/S | $51.35 +0.75% | 6.8% | 13.1M | $360.8M |
| 5 | NASDAQ: SYRE SPYRE THERAPEUTICS INC | $97.63 −3.77% | 6.4% | 3.8M | $341.0M |
| 6 | NASDAQ: APGE APOGEE THERAPEUTICS INC | $135.07 0.00% | 3.9% | 1.6M | $209.2M |
| 7 | NASDAQ: ORKA ORUKA THERAPEUTICS INC | $97.57 +1.91% | 3.8% | 2.1M | $204.1M |
| 8 | NASDAQ: TNGX TANGO THERAPEUTICS INC | $22.71 +3.75% | 3.7% | 6.4M | $198.7M |
| 9 | NASDAQ: BLTE BELITE BIO INC | $151.02 −3.33% | 3.6% | 1.2M | $189.8M |
| 10 | NASDAQ: ERAS ERASCA INC | $14.22 +3.34% | 3.3% | 9.6M | $175.0M |
| 11 | NASDAQ: TARS TARSUS PHARMACEUTICALS INC | $77.67 +2.26% | 3.3% | 2.8M | $174.7M |
| 12 | NASDAQ: ALNY ALNYLAM PHARMACEUTICALS INC | $147.82 −1.06% | 2.7% | 480K | $144.5M |
| 13 | NASDAQ: INSM INSMED INC | $144.46 +20.58% | 2.6% | 1.3M | $141.4M |
| 14 | NASDAQ: MBX MBX BIOSCIENCES INC | $53.41 −0.02% | 2.6% | 2.5M | $138.4M |
| 15 | NASDAQ: PCVX VAXCYTE INC | $58.36 −0.27% | 2.3% | 2.1M | $123.7M |
| 16 | NASDAQ: VRDN VIRIDIAN THERAPEUTICS INC | $31.44 +4.38% | 2.3% | 6.7M | $123.5M |
| 17 | NASDAQ: OLMA OLEMA PHARMACEUTICALS INC | $7.15 +1.27% | 2.0% | 8.7M | $108.5M |
| 18 | NASDAQ: JBIO JADE BIOSCIENCES INC | $15.06 −2.78% | 1.2% | 2.9M | $63.5M |
| 19 | NASDAQ: TYRA TYRA BIOSCIENCES INC | $19.73 +0.61% | 1.1% | 1.8M | $58.4M |
| 20 | NASDAQ: ASMB ASSEMBLY BIOSCIENCES INC | $22.50 +0.49% | 0.8% | 1.6M | $42.7M |
| 21 | NASDAQ: EYPT EYEPOINT INC | $0.26 −2.87% | 0.8% | 2.9M | $41.3M |
| 22 | NASDAQ: ACHV ACHIEVE LIFE SCIENCE INC | $5.92 −3.58% | 0.6% | 5.0M | $32.3M |
| 23 | NASDAQ: VOR VOR BIOPHARMA INC | $18.52 +3.87% | 0.6% | 1.8M | $32.2M |
| 24 | NASDAQ: MPLT MAPLIGHT THERAPEUTICS INC | $6.42 −3.46% | 0.5% | 686K | $24.6M |
| 25 | NASDAQ: KARD KARDIGAN INC | — — | 0.4% | 900K | $21.5M |
Showing 1–25 of 28 positions on this page reported in this 13F.
- Healthcare100%
- AddedNUVLNUVALENT INC+11.3%$731.7M
- AddedEWTXEDGEWISE THERAPEUTICS INC+38.7%$415.1M
- AddedGMABGENMAB A/S+64.8%$360.8M
- AddedSYRESPYRE THERAPEUTICS INC+96.2%$341.0M
- AddedAPGEAPOGEE THERAPEUTICS INC+16.9%$209.2M
- AddedTNGXTANGO THERAPEUTICS INC+58.6%$198.7M
- AddedBLTEBELITE BIO INC+10.6%$189.8M
- AddedTARSTARSUS PHARMACEUTICALS INC+8.3%$174.7M
- NewALNYALNYLAM PHARMACEUTICALS INC—$144.5M
- AddedINSMINSMED INC+5.7%$141.4M
- ReducedRVMDREVOLUTION MEDICINES INC−4.4%$1.2B
- ReducedORKAORUKA THERAPEUTICS INC−7.6%$204.1M
- ReducedERASERASCA INC−8.1%$175.0M
- ReducedPCVXVAXCYTE INC−55.6%$123.7M
- ReducedTYRATYRA BIOSCIENCES INC−11.0%$58.4M
- ReducedEYPTEYEPOINT INC−8.0%$41.3M
- ReducedLXEOLEXEO THERAPEUTICS INC−32.5%$19.4M
- SoldCNTACENTESSA PHARMACEUTICALS PLC−100%—
- SoldABVXABIVAX SA−100%—
- SoldMAZEMAZE THERAPEUTICS INC−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | ACHV Achieve Life Sciences, Inc. | 13G | 9.2% | 9.9M | Filed 24 APR 2026 |
| 2 | OBX Obsidian Therapeutics, Inc. | 13G | 6.6% | 4.1M | Filed 05 OCT 2026 |
| 3 | LXEO Lexeo Therapeutics, Inc. | 13G | 6.5% | 4.8M | Filed 17 FEB 2026 |
| 4 | TYRA Tyra Biosciences, Inc. | 13G | 5.8% | 3.5M | Filed 17 SEP 2026 |
Showing all 4 disclosed stakes.
Reading Paradigm Biocapital Advisors LP’s 13F portfolio
Paradigm Biocapital Advisors LP’s $5.3B 13F book is spread across 28 reported positions and is highly concentrated — its ten largest positions alone are 75% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are RVMD, NUVL, EWTX, GMAB and SYRE, led by REVOLUTION MEDICINES INC (RVMD) at 22% of the portfolio. The heaviest sector exposure is Healthcare (100%).
What Paradigm Biocapital Advisors LP changed last quarter
Between 2026-03-31 and Q2 2026, Paradigm Biocapital Advisors LP was roughly balanced between buying and selling: it opened 7 new positions and added to 12 more, while trimming 7 and closing 14 outright. Against a 28-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was NUVALENT INC (NUVL), and its biggest reduction was REVOLUTION MEDICINES INC (RVMD).
What a 13F does and doesn’t reveal
A 13F captures only Paradigm Biocapital Advisors LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Paradigm Biocapital Advisors LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Paradigm Biocapital Advisors LP's profile on this page is built directly from those filings.
How current is the 13F data on Paradigm Biocapital Advisors LP's page?
It reflects Paradigm Biocapital Advisors LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Paradigm Biocapital Advisors LP files its next quarterly report, this page refreshes automatically.
Can I see Paradigm Biocapital Advisors LP's complete list of holdings?
This page highlights Paradigm Biocapital Advisors LP's largest positions rather than all 28 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Paradigm Biocapital Advisors LP's filings.
Does a 13F show everything Paradigm Biocapital Advisors LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Paradigm Biocapital Advisors LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Paradigm Biocapital Advisors LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

